Skip to content
10-Q

Quarterly Report

CHINA PHARMA HOLDINGS, INC. CPHI

0001213900-26-057705

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 40.52M sh
Shares Diluted Q1 2026 · Mar 31, 2026 25.6M sh
Shares Diluted Q1 2026 · Mar 31, 2025 3.26M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$55.29K
Operating Cash Flow restated Q1 2026 · Mar 31, 2025 −$73.68K
Short Term Debt Q1 2026 · Mar 31, 2026 $1.47M
Short Term Debt Q1 2026 · Dec 31, 2025 $1.44M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $168.47K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $345.11K
Stockholders Equity Q1 2026 · Mar 31, 2026 $37.02M
Stockholders Equity Q1 2026 · Dec 31, 2025 $22.74M
Stockholders Equity Q1 2026 · Mar 31, 2025 $6.97M
Stockholders Equity Q1 2026 · Dec 31, 2024 $7.75M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.27M
Current Liabilities Q1 2026 · Dec 31, 2025 $7.4M
Total Liabilities Q1 2026 · Mar 31, 2026 $8.12M
Total Liabilities Q1 2026 · Dec 31, 2025 $8.26M
Current Assets Q1 2026 · Mar 31, 2026 $2M
Current Assets Q1 2026 · Dec 31, 2025 $2.35M
Total Assets Q1 2026 · Mar 31, 2026 $45.14M
Total Assets Q1 2026 · Dec 31, 2025 $31M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.04
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.24
Eps Basic Q1 2026 · Mar 31, 2026 −$0.04
Eps Basic Q1 2026 · Mar 31, 2025 −$0.24
Sga Expense Q1 2026 · Mar 31, 2026 $1.23M
Sga Expense Q1 2026 · Mar 31, 2025 $507.18K
Rd Expense Q1 2026 · Mar 31, 2026 $83.76K
Rd Expense Q1 2026 · Mar 31, 2025 $29.59K
Net Income Q1 2026 · Mar 31, 2026 −$1.14M
Net Income Q1 2026 · Mar 31, 2025 −$785.57K
Operating Income Q1 2026 · Mar 31, 2026 −$1.12M
Operating Income Q1 2026 · Mar 31, 2025 −$758.62K
Gross Profit Q1 2026 · Mar 31, 2026 $285.49K
Gross Profit Q1 2026 · Mar 31, 2025 −$136.06K
Cost Of Revenue Q1 2026 · Mar 31, 2026 $698.05K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $1.27M
Revenue Q1 2026 · Mar 31, 2026 $983.54K
Revenue Q1 2026 · Mar 31, 2025 $1.14M
Capex Q1 2026 · Mar 31, 2025 $58.32K